Cytosorbents Corp. 2010 Form 10-K Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2010, for Cytosorbents Corp. (formerly MedaSorb Technologies Corporation). The company is a development-stage medical device firm headquartered in Monmouth Junction, New Jersey. Its primary focus is the commercialization of CytoSorb™, a blood purification device designed to remove middle molecular weight toxins (cytokines) from the blood to treat sepsis and other critical care conditions. The company also holds technology for BetaSorb™, intended for chronic kidney failure, though this is not the current commercial focus.
As of the reporting date, the company had no commercial revenue. In March 2011 (subsequent to the fiscal year-end), the company received European CE Mark approval for CytoSorb™ as an extracorporeal cytokine filter and achieved ISO 13485:2003 certification.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,908,865) | $(2,736,715) |
| Accumulated Deficit | $(83,988,850) | $(78,902,521) |
| Cash and Cash Equivalents | $1,055,669 | $1,595,628 |
| Current Liabilities | $1,219,119 | $970,765 |
| Long-Term Debt (Convertible Notes) | $1,077,388 | $0 |
| Research & Development Expenses | $1,757,370 | $1,961,960 |
| General & Administrative Expenses | $759,387 | $757,450 |
Note: The filing does not provide specific margin data as there is no revenue. Liquidity is constrained by a working capital deficit.
Material Changes vs. Prior Period
- Debt Financing: The company issued $1,335,250 in 24-month convertible promissory notes during 2010, creating a new long-term liability category that was absent in 2009.
- Equity Issuance: Significant common stock was issued in 2010, including sales under a purchase agreement with Lincoln Park Capital Fund (LPC) and conversions of preferred stock, increasing the share count from approximately 66.4 million to 122.8 million.
- Grant Income: The company recognized approximately $604,000 in grant income in 2010 (primarily from the QTDP program), recorded as a reduction of R&D expenses, compared to $99,000 in 2009.
- Preferred Stock Dividends: Non-cash preferred stock dividends increased significantly to $2,177,464 in 2010 from $704,325 in 2009, driven by a change in valuation methodology and the accumulation of accrued dividends.
Guidance, Outlook, and Risks
Outlook and Commercialization: Management intends to begin commercializing CytoSorb™ in the European Union in the second half of 2011, contingent on funding. The company plans to conduct additional clinical studies in sepsis and other critical care diseases. No specific financial guidance was provided.
Going Concern: The auditors' report expresses substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. The company requires significant additional financing to fund clinical studies and commercialization.
Key Risks:
- Capital Requirements: The company has limited cash ($1.06M) against current liabilities ($1.22M) and must raise additional funds to survive beyond late 2011.
- Regulatory Uncertainty: While CE Mark approval was obtained in Europe, FDA approval for the U.S. market is not guaranteed and requires further clinical trials.
- Market Acceptance: There is no assurance that the medical community will accept the device or that reimbursement will be secured.
- Intellectual Property: The company faces potential litigation risks regarding patents, including past disputes with Purolite (settled) and potential conflicts with Dow Chemical.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and the status of the funding agreement with Lincoln Park Capital Fund (LPC) to confirm the ability to fund operations through 2011.
- Commercialization Timeline: Confirm the actual launch date of CytoSorb™ in Europe and the progress of the controlled-market release planned for late 2011.
- Preferred Stock Terms: Review the terms of Series A and Series B Preferred Stock, specifically the dividend rates (10% vs. 20% upon default) and conversion prices, as these significantly impact common shareholder dilution.
- Convertible Notes: Assess the terms of the $1.3M+ in convertible notes issued in 2010 and the subsequent $1.25M notes issued in Feb 2011, including conversion rates and warrant coverage.
- Regulatory Status: Monitor the status of FDA filings (510(k) or PMA) and any updates on the European Sepsis Trial data analysis.